S-1410-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Amy Klobuchar (D-MN)
What it does
The Find It Early Act would require health insurers, Medicare, Medicaid, TRICARE, and the VA to cover additional breast cancer screening and diagnostic imaging — including mammograms, ultrasounds, MRI, and molecular breast imaging — at no cost to the patient. Coverage would apply to individuals deemed at increased risk for breast cancer or who have dense breast tissue, as determined by American College of Radiology or National Comprehensive Cancer Network guidelines. The bill would take effect January 1, 2026, and would also extend these requirements to grandfathered health plans that are currently exempt from many ACA coverage mandates.
Who benefits
Women and men at elevated breast cancer risk due to genetics (e.g., BRCA variants), family history, age, race, or ethnicity — particularly Black women, who face higher breast cancer mortality rates. Individuals with dense breast tissue, estimated at 40–50% of women who get mammograms. Medicare beneficiaries and Medicare Advantage enrollees who currently face cost-sharing for supplemental screenings. Medicaid enrollees in states that currently impose cost-sharing on diagnostic imaging. Veterans and active-duty military dependents enrolled in TRICARE who currently pay out-of-pocket for additional screenings. Radiology providers and imaging centers that would see increased utilization. Employers and insurers who may see reduced long-term costs from earlier-stage cancer detection.
Who is hurt
Private insurers and Medicare Advantage plans that would absorb the cost of additional screenings currently subject to cost-sharing. Employers sponsoring group health plans, including grandfathered plans, who would face new mandatory coverage requirements and associated premium pressure. Taxpayers who fund Medicare, Medicaid, and VA programs, which would bear increased federal spending. Competing diagnostic technologies or providers not listed in the bill's approved modalities, who may face indirect disadvantage. States that would need to update Medicaid plans and potentially pass enabling legislation, incurring administrative costs.
Supporters argue
Supporters argue that cost-sharing is a documented barrier to supplemental screening, and that delayed detection of breast cancer in high-risk individuals leads to later-stage diagnoses that are more expensive to treat and more likely to be fatal. They contend that dense breast tissue — present in roughly 40–50% of women screened — significantly reduces mammogram accuracy, making supplemental imaging medically necessary rather than elective. Supporters further argue that the bill addresses documented racial disparities: Black women are 40% more likely to die from breast cancer than white women despite similar incidence rates, and that removing financial barriers to guideline-recommended screening is a targeted, evidence-based intervention.
Opponents argue
Opponents argue that mandating unlimited-frequency screening with no cost-sharing could incentivize overutilization, leading to false positives, unnecessary biopsies, patient anxiety, and higher system-wide costs without proportionate survival benefit — concerns raised by the U.S. Preventive Services Task Force regarding aggressive supplemental screening protocols. They contend that delegating coverage determinations to private professional bodies like the American College of Radiology and the National Comprehensive Cancer Network, rather than to a federal standard-setting process, creates an unusual and potentially unaccountable mechanism for defining mandatory insurance benefits. Opponents also argue that extending these mandates to grandfathered health plans disrupts settled employer expectations and may accelerate plan terminations.
Constitutional context
Congress regulates private insurance markets under the Commerce Clause (Art. I, §8, cl. 3) and funds Medicare and Medicaid under the Taxing and Spending Clause (Art. I, §8, cl. 1). NFIB v. Sebelius (2012) affirmed broad congressional authority to regulate existing commercial activity in insurance markets and to attach conditions to federal healthcare funding, though it cautioned that Medicaid conditions cannot be so coercive as to leave states no genuine choice. Post-Loper Bright (2024), courts will independently review whether delegating coverage-trigger determinations to private professional organizations (ACR, NCCN) constitutes a permissible statutory standard or an unlawful delegation of federal rulemaking authority.
Checks and balances
Congress expands coverage mandates across multiple federal programs; HHS and the VA Secretary implement the requirements; courts retain authority to review the delegation of coverage standards to private medical organizations and any Spending Clause coercion challenges from states regarding Medicaid compliance.
Historical precedent
The ACA (2010) established the framework for no-cost preventive care under Section 2713 of the Public Health Service Act, and the Supreme Court in NFIB v. Sebelius (2012) upheld Congress's authority to attach coverage mandates to federal healthcare funding, though it struck down the Medicaid expansion's coercive all-or-nothing funding condition.